
## Shidong Lv

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5686327/publications.pdf Version: 2024-02-01



SHIDONGLY

#	Article	IF	CITATIONS
1	Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene, 2018, 37, 1354-1368.	5.9	101
2	PPARÎ <sup>3</sup> activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer, 2019, 19, 204.	2.6	64
3	Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3. Epigenetics, 2019, 14, 1194-1208.	2.7	36
4	Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	30
5	HOTAIR expands the population of prostatic cancer stem-like cells and causes Docetaxel resistance via activating STAT3 signaling. Aging, 2020, 12, 12771-12782.	3.1	18
6	Leukemia Inhibitory Factor Receptor Suppresses the Metastasis of Clear Cell Renal Cell Carcinoma Through Negative Regulation of the Yes-Associated Protein. DNA and Cell Biology, 2018, 37, 659-669.	1.9	17
7	Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma. Cancer Gene Therapy, 2022, 29, 573-584.	4.6	12
8	Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells. Prostate, 2021, 81, 893-901.	2.3	6